$4.98
-0.10 (-1.97%)
Open$5.03
Previous Close$5.08
Day High$5.12
Day Low$4.96
52W High$7.75
52W Low$3.71
Volume—
Avg Volume206.4K
Market Cap121.51M
P/E Ratio—
EPS$-1.07
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+640.0% upside
Current
$4.98
$4.98
Target
$36.85
$36.85
$27.29
$36.85 avg
$45.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.36M | 21.48M | 20.04M |
| Net Income | -30,346,819 | -5,165,355 | -3,853,498 |
| Profit Margin | -267.1% | -24.1% | -19.2% |
| EBITDA | -32,207,765 | -6,655,427 | -5,995,002 |
| Free Cash Flow | — | -3,535,951 | -2,421,928 |
| Rev Growth | — | -8.7% | +0.8% |
| Debt/Equity | — | 0.24 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |